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ABSTRACT: 
Objectives: Many rheumatoid arthritis (RA) patients report pain despite excellent control of 
inflammation with immunotherapies. Variable degrees of co-existing fibromyalgia (FM) may explain 
this disparity. FM has been characterised by aberrant brain functional connectivity, especially 
between the Default Mode Network (DMN)  and insula. We hypothesised that RA patients reporting 
the highest 2011 ACR FM survey criteria scores- a continuous measure of FM degree also known as 
fibromyalgianess (FMness)- would demonstrate functional connectivity abnormalities similar to FM.   
Methods: RA patients underwent an 11 min functional connectivity MRI brain scan (fcMRI) and a 
clinical evaluation which included a measure of FMness. Brain networks were isolated from FcMRI 
data. Individual patient network to whole brain connectivity analyses were then conducted followed 
by group level regression which correlated the connectivity of each network with FMness. Results 
were significant on the cluster level with a family wise error (FWE) rate p-value <0.05 derived from 
an uncorrected voxel level p-value <0.001. 
Results: 54 patients participated (mean age 54.9years; 75.9% female; mean FMness score 13.3 
[range 1-29]). From the whole brain analyses, a single significant positive correlation between DMN 
connectivity to the left mid/posterior insula and FMness (r=0.58, p=0.001 FWE) was demonstrated.  
Conclusions: RA patients who have increased levels of FMness appear to share neurobiological 
features consistently observed in FM patients. This study is the first to provide neuroimaging 
evidence that RA is a mixed pain state, with many patients’ symptoms being related to CNS rather 
than classic inflammatory mechanisms. 
 
INTRODUCTION: 
Rheumatoid arthritis (RA) is an archetypal chronic inflammatory disorder which is principally 
characterised by peripheral joint pain, stiffness and swelling. In recent times, management has been 
revolutionised by the early and aggressive application of anti-inflammatory therapies.  These 
advances have led to tremendous average improvements in objective outcomes and even disability, 
but as many as 50% of patients continue to report clinically significant levels of pain despite 
excellent control of their peripheral inflammation1,2.  
This disconnect between improvements in inflammation and improvements in pain suggests that 
there is a likely contribution of pain mechanisms which are in addition to and distinct from 
peripheral inflammation. Central sensitisation - a consequence of dysfunctional central nervous 
system pain processing which defines the primary chronic pain syndrome of fibromyalgia (FM) - may 
represent one such mechanism3. This possibility is supported by clinical epidemiological research 
which has evidenced co-existing FM in 13-25% of RA patients4.  This compares to a prevalence of 1-
5% in the general population5. A further 7-15% of RA patients have hallmark features of FM (which 
include somatic symptoms such as fatigue as well as chronic pain) without meeting formal 
classification criteria4. Wolfe and colleagues derived a continuous scale from the ACR FM survey 
criteria and found it to predict pain and disability in RA even among patients who did not fully satisfy 
the FM criteria. The term fibromyalgianess (FMness) was subsequently introduced to reflect this 
wide phenotypic range6.   
There are very few studies that examine whether the prevalent FMness phenotype in RA is 
underpinned by the same central sensitisation pathways as demonstrated in ‘primary’ FM.  If true, it 
would greatly enhance the argument for ‘primary’ FM therapeutic approaches (which are quite 
distinct to current peripherally directed anti-inflammatory RA therapies) benefitting RA patients who 
have clinical features of FMness. 
Advanced neuroimaging techniques have been crucial in delineating the neurobiological features of 
central sensitisation in ‘primary’ FM, but have not previously been applied to concomitant FM in RA. 
Recent studies have employed functional connectivity MRI (fcMRI) - an adaptation of functional MRI 
data that examines temporal correlations in the MRI signal across various brain networks and 
regions. These connections are thought to be important for the maintenance of synaptic 
connectivity and as such modulates the efficiency and extent of neuronal transmission in the brain.   
Among FM patients, the dorsal attention (DAN), sensori-motor (SMN) and salience (SLN) brain 
networks have been implicated with increased connectivity to pro-nociceptive brain areas and 
decreased connectivity to anti-nociceptive brain areas7-9. However, currently the most convincing 
and reproducible fcMRI evidence relates to the association between the default mode network 
(DMN) and insular cortex – otherwise implicated with self-referential10 and multimodal sensory 
processing respectively11.  This specific connection is cross-sectionally associated with FM and pain 
intensity12 and longitudinally associated with change of FM pain following both efficacious 
pharmacological (pregabilin) and non-pharmacological treatments (acupuncture)13,14. The robustness 
of this finding is further corroborated by magnetoencephalography (a more direct measure of brain 
connectivity)15-17.   These same patterns have been noted in other conditions known to be 
accompanied by central sensitization, such as irritable bowel syndrome and low back pain16,17.   
Together this data indicates that functional connectivity – and specifically DMN-Insular 
hyperconnectivity – may be a key biological marker of both the presence and severity of FM related 
pain, and central sensitisation.   
As yet, no studies have investigated whether fcMRI features of FM are observed in RA patients with 
co-occurring FM. Specifically we hypothesised that that RA patients reporting the highest levels of 
FMness would demonstrate fcMRI features of FM.   
 
PATIENTS & METHODS: 
Patients: 
335 RA Patients were approached through a UK regional rheumatology service.  Of those, 193 
indicated interest in the study.  Participants were considered eligible if they met the 2010 American 
College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification 
criteria18, and had a clinically significant level of fatigue for at least 3 months (defined as a score > 3 
on the Chalder fatigue binary scale (CFS)19.  Exclusion criteria were contra-indications to MRI and 
left-handedness.  73 patients fulfilled these criteria and ultimately, 54 RA patients completed the 
study.  
All consenting participants underwent a clinical evaluation. This included a measure of FMness using 
the ACR FM survey criteria which combines a measure of widespread pain (number of painful sites 0-
19) with a symptom severity scale (e.g., fatigue, subjective cognitive problems, headache, poor 
mood, scores range 0-12)20. In addition their levels of systemic inflammation (C reactive protein, 
CRP), disease activity (DAS28), current levels of overall fatigue and pain severity (0-10 numerical 
rating scale), sleep disturbance (Jenkin’s sleep scale21 and depression (Hospital Anxiety and 
Depression Scale22) were recorded. Participants then undertook a fMRI brain scan.   
Data Acquisition: 
Each participant completed an 11-minute functional scan while performing the Paced Auditory Serial 
Attention Test (PASAT), a validated measure of cognitive function (auditory processing, calculation, 
working memory, attention) which has been previously used in an fMRI context23.  The PASAT was 
given in a block design with 3x3 minute ‘on’ periods, interspersed with 4x30 second rest periods. The 
functional images were acquired by a 3 Tesla (Achieva X-series, Philips Medical, Best, The 
Netherlands) 8 channel phased array head coil using a T2*-weighted gradient-echo single-shot echo-
planar imaging pulse sequence with the following parameters: TR = 3000 ms, TE = 30 ms, flip angle 
(FA) = 90°, in-plane SENSE acceleration 2, matrix size 128 × 128 with 30 slices, field of view (FOV) = 
240 mm, 1.88 mm × 1.88 mm × 5 mm voxels and 226 volumes.  The first four volumes were 
discarded to avoid equilibration effects. A high-resolution structural T1-weighted fast-field echo 3D 
structural scan was collected for normalization (TR = 8.2  ms, TE = 3.8 ms, TI = 1018 ms FA = 8°, FOV 
= 240 mm, matrix size 240 × 240 matrix with 160 slices and 0.94 mm × 0.94 mm × 1 mm voxels). 
Preprocessing: 
All data were checked for motion greater than 3.76mm and 5° rotation and visually inspected for 
artifacts.  No participants were excluded for these reasons. FcMRI data were preprocessed using 
SPM8 (Wellcome Department of Cognitive Neurology, London, United Kingdom) running on MATLAB 
R2014a (Mathworks, Sherborn, MA, USA), as previously described23.  Briefly, the functional images 
were realigned, and the structural image was co-registered to mean functional image and then 
segmented.  The structural and functional scans were normalized to the standard SPM Montreal 
Neurological Institute template grey prior probability map via the individuals segmented grey matter 
image.  Functional scans were smoothed with an 8-mm FWHM Gaussian kernel.  
Independent Component Analysis (ICA):  
We performed Group ICA using the Group ICA of fMRI Toolbox (GIFT) to create group specific 
network masks24. Component estimates were validated using ICASSO software25 over 20 iterations to 
ensure the accuracy and reliability of results. Subject specific spatial maps and time courses were 
generated using the GICA3 back-reconstruction method.  The networks of interest were the: DMN, 
SMN, SLN and DAN.  These components were verified by spatial correlation between the component 
maps and previously identified templates26.  Spatial masks of the mean component map for each 
network were created using the Marsbar toolbox for seed-based connectivity analyses.  
Network to whole brain connectivity analysis:  
The preprocessed functional data were entered into the Functional Connectivity Toolbox (CONN; 
Cognitive and affective neuroscience laboratory, Massachusetts Institute of Technology, Cambridge, 
MA, USA; www.nitrc.org/projects/conn) v15 in SPM827.  A nuisance regression using the CompCor 
method28 was performed with six subject-specific motion parameters, the signal from white matter 
and CSF, and their first order derivatives included as confounds.  A band pass filter (0.01-0.1 Hz) was 
applied to remove linear drifts and high frequency noise in the data. The mean component maps 
generated from ICA were used as seeds.  Beta maps for each individual representing connectivity 
between the network of interest and the rest of the brain were generated.  The task beta maps were 
then passed onto second-level group analyses in SPM8.  Using a multiple regression model, we 
assessed the association between network-whole brain connectivity and FMness with age and sex 
originally included as covariates of no interest, followed by additional corrections for the putative 
confounders of CRP and amitriptyline use.  The resulting maps were thresholded at an uncorrected 
voxelwise p > 0.001, and significance was set at p < 0.05 family wise error (FWE) cluster corrected for 
multiple comparisons.  The average fisher transformed r values of significant clusters were extracted 
from the first level beta maps for each subject using Marsbar.  These values were brought into 
STATA 12.1 (Stata, College Station, TX, USA) to enable sensitivity analyses and test post-hoc 
correlations analyses with disease and symptom measures.    
 
RESULTS: 
Clinical Characteristics: 
In total, 54 patients completed the study.  The mean age was 54.9 ± 11.41 years, n = 41 female and 
the mean disease duration was 11.49 ± 8.64 years.  The mean FMness score was 13.20 ± 6.21 [range 
1-29] and n=5 were receiving pharmacological treatment for FM (all low dose amitriptyline).  Other 
patient characteristics are displayed in Table 1.  
[Insert table 1] 
DMN-Insula functional connectivity is associated with FMness in RA: 
There was a significant positive correlation between DMN connectivity to the left mid/posterior 
insula and FMness (r=0.572, p = 0.001 FWE corrected) in RA patients.  The association remained 
significant after controlling for age and sex (r = 0.577, p = 0.001 FWE corrected, see Figure 1).  
Further, analyses correcting for the putative confounding factors of inflammation (CRP) and 
amitriptyline usage did not alter this observation  (r = 0.568, p = 0.001 FWE corrected and r = 0.556, 
p = 0.009 FWE corrected, respectively).  No other significant correlations were identified to any of 
the other networks of interest. Further, a sensitivity analysis of only those patients (n=27) who did 
not fulfil ACR preliminary criteria for FM (total score <13) observed the correlation between DMN-
insula and FMness to remain highly significant (p=0.006, r-0.51). 
[Insert figure 1] 
We then examined correlations with phenotypic features (table 2).  First, the individual components 
of the FMness score were examined, the widespread pain index and the symptom severity scale, in 
order to establish if the DMN-Insula connectivity relationship was directed by one or both 
components.  Both the widespread index (r=0.50, p<0.0001) and symptom severity sale (r=0.41, 
p=0.002) were significantly associated indicating important contributions for both.  This was further 
corroborated by significant associations with chronic fatigue (p=0.002) and sleep disturbance 
(p=0.02), although interestingly no association existed between DMN-insula and pain reported at the 
time of the scan (p=0.52). We next explored correlations between the identified functional 
connection and RA disease features. Overall disease activity (DAS28) was significantly correlated 
(p=0.002), although CRP was not (p=0.19).  
DISCUSSION: 
To our knowledge, this study is the first to provide objective neuroimaging evidence that RA is a 
mixed pain state displaying characteristics of central sensitisation.   RA patients who reported high 
levels of FMness demonstrated significantly higher functional connectivity between the DMN and 
insula - a recognised neurobiological feature of ‘primary’ FM. Further, the ACR FM survey appears to 
be a strong surrogate for this neurobiological marker of central sensitisation and, in the future, could 
be a useful tool to support clinicans’ evaluation of pain and inform subsequent management. 
Our group and others have previously identified significant alterations in DMN-insula connectivity in 
FM.  The insula is a highly connected region of the brain with multiple functional features which 
routinely involve the integration and conversion of physiological inputs into higher level outputs29.  
Numerous studies have implicated the insula with different disorders and dimensions of pain, 
including FM30.  Its purported role as a key relay station in pain processing has been supported by 
direct electric stimulation studies of the region which have effected painful sensations in some 
patients31.  The DMN comprises synchronously functioning regions - including the posterior cingulate 
cortex, medial prefrontal cortex and lateral parietal lobes - which are commonly associated with 
activities of introspection and are also found to be disrupted in chronic pain32. It is unknown whether 
this network is a modulator of pain (potentially via descending inhibitory pathways33) and/or related 
somatic features, or exclusively a consequence of chronic pain exposure32. Given these possible 
complementary roles in pain processing, it is plausible to speculate that DMN and insula may be 
functionally connected in FM12-15.  
In this current study we expand on these findings by identifying a significant alteration of the very 
same functional connection in relation to phenotypic features of FM co-existing in another chronic 
pain disorder (with a distinct primary pathophysiology relating to inflammation).  Presence of this 
connection despite the apparent absence of an association with significant concurrent peripheral 
inflammation or overall levels of pain further supports the apparent specificity of the DMN-insula 
connection as a marker of a distinct pain sub-type.  It is however interesting to consider the 
significant correlation with the DAS28 which appears to be prinicipally driven by tender and not 
swollen joint counts.  This aligns with many studies which have observed a conflation of DAS28 in 
the context of FM which in turn leads to greater biological therapies. That said, we cannot discount 
the possibility that inflammation may be implicated in central sensisitisation.   
Although no other study has applied neuroimaging to characterise FM in a co-existing disorder, 
dysfunctional DMN-insula functional connectivity has been observed in irritable bowel syndrome16, 
chronic back pain17, and migraine34 – all  pain conditions where central sensitisation has been 
implicated35.  Of interest, these conditions are also associated with somatic symptoms36,37 which 
aligns with our post-hoc analysis indicating that the DMN-insula functional connection relates not 
only to pain but to symptoms such as fatigue and cognitive dysfunction also (as measured by the 
Symptom Severity Index). A final point to note is that this connection remains significant even 
among those patients who do not fulfil ACR criteria, further evidencing that FM is a continuous 
rather than discrete construct.   
Our findings indicate that centralised pain pathways co-exist with more established peripheral 
inflammatory driven pathways in RA. This is corroborated by QST studies which allude to 
dysfunctional CNS pain pathways in RA by consistently evidencing hyperalgesia and allodynia38. 
Specifically, lower pain-pressure thresholds have been measured across both diseased joints and 
non-joint sites in RA patients with concomitant FM in comparison to RA patients without39. 
Our study builds on the few functional neuroimaging studies to have been conducted in RA. 
Although previous studies have been small and limited to provoked acute experimental pain at the 
site of joints (rather than non-diseased sites). They have provided evidence supporting a role of 
mixed CNS mechanisms in RA related pain.  Jones et al originally reported differential cortical 
responses to acute pain using PET between RA (n=6) and a chronic pain population characterised by 
depression and dysfunctional coping. They subsequently speculated that the CNS mechanisms of 
inflammatory pain were distinct to other pain types40. More recently, Rech and colleagues 
undertook evoked pain fMRI pre and post anti-TNF therapy in n=10 RA patient and observed 
differences in brain activations between responders and non-responders 41.  This again infers the 
possible existence of different neural signatures for different types of pain since responders are 
more likely to be characterised by pain of inflammatory origin in comparison to non-responders.  
This present study is strengthened by its large sample study (n=54) – to our knowledge the largest 
neuroimaging investigation of any inflammatory rheumatic disease, thus reducing the risk of the 
false positive results which are endemic in neuroscience.  The robustness of these results are further 
enhanced by our conservative analytical methodology. Despite employing a data driven global scan 
approach, only the key DMN-insula functional connection was identified. Furthermore, this data was 
acquired using a scanner in a centre which has previously not contributed to the literature 
evidencing the importance of this connection. Finally, replication of this specific pattern of co-
activation in the context of a task (rather than resting state – as with previous studies) not only 
strengthens validity but also enhances existing views that fcMRI largely reflects intrinsic 
communication networks which are unrelated to conscious activities42.  
Certain limitations to this study should also be considered. Firstly, although the study population 
includes a demographically representative cohort of RA patients with a mixture of disease activity 
states, there was a bias towards selecting patients with significant fatigue levels. This sample 
enrichment however enabled greater power to detect the mechanistic associations inherent to the 
research question. It also cannot be assumed that these findings may generalise to other rheumatic 
conditions, and this intriguing possibility should be the subject of future experiments.  Secondly, due 
to the cross-sectional design, no assumption can be made regarding whether DMN-insula functional 
connectivity has causal role in FMness. This data does, however, re-inforce previous studies which 
propose this connection at least as a biological marker of the FM construct and so adequate to 
address our primary research question. Thirdly, despite being the largest study of its kind, the 
sample size cannot confidently exclude the existence of other relevant network to region 
connections (which most likely exist) and still lacks sufficient power to fully and independently 
correct for the multiple putative confounding variables which are implicated with FM. That said, our 
results remained significant following individual adjustments of age and sex. The latter is of 
particular interest because previous studies of functional connectivity in ‘primary’ FM have consisted 
almost entirely of females. Since numerous sex differences in FM biology have been reported43, the 
generalisability observed here serves to enhance the usefulness of the DMN-insula marker further.   
We have shown that central sensitisation is not confined to individuals with ‘primary’ FM and co-
exists in patients with the biologically distinct disorder of RA. Such evidence for shared mechanisms 
could inform future clinical decision making.  It is challenging for physicians to distinguish different 
pain states in patients, particularly those with a pre-existing chronic pain disorder. This is especially 
true since the centralised pain state of FMness is not only common but also artificially inflates 
routinely used measures of peripherally based inflammatory pain states (e.g. DAS28)6 which are 
pivotal in guiding clinicians prescriptions of anti-inflammatory treatment. In consequence 
inappropriate prescribing of anti-inflammatory therapies for pain which is actually not inflammatory 
in origin is likely common and probably a principal factor for why many RA patients continue to 
report pain following anti-inflammatory therapy despite apparent resolution of inflammation1.  RA 
patients reporting significant pain and who have evidence of high levels of functional connectivity 
between the insula and DMN are more likely to benefit from centrally acting therapies which are 
effective for FM instead of or in addition to anti-inflammatory therapies. These currently include 
both pharmacological (e.g. neuroleptics) and non-pharmacological (e.g. CBT) agents44.  
Unfortunately limited access, expense and specialised analysis requirements will likely prohibit 
implementation of fcMRI into routine practice, however this technology may not be essential given 
the demonstrated relationship with the FM ACR Survey score.  Instead application of this measure as 
a point of care tool may enable clinicians to quantify the contribution of central sensitisation to their 
patient’s pain and subsequently inform management choices. Future refinements and abbreviations 
to this tool will hasten translation. Moreover since co-existing FM is a common issue among many 
diseases (musculoskeletal and beyond)45-49, such a tool may be generically applicable and so testing 
across the spectrum of chronic pain disorders may finally move the pain field into the era of 
personalised medicine. 
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 Figure 1: Increased brain connectivity between the DMN and Left Mid/Posterior Insula in 
rheumatoid arthritis patients is associated with fibromyalgianess. Scatter plots show positive 
correlations for interindividual differences in brain connectivity (Fisher transformed r-values; x-axis) 
and the total ACR fibromyalgia score (y-axis). 
 
 
Table 1: Clinical characteristics 
Clinical features 
RA disease activitya  3.62±1.30 
CRP (mg/L) 7.78±8.54 
Fatigueb 4.59±2.19 
Depressionc 6.89±3.92 
Sleep disturbancee 15.67±5.46 
Current overall painf 3.81±2.38 
aDisease activity score 28; bCurrent fatigue 0-10 numerical rating scale (NRS); cHospital anxiety & 
depression scale; eJenkin’s sleep scale; f Current pain NRS 
 
 
 
Table 2: Disease and symptom correlations with DMN-Insula 
Phenotypic features Correlationg P value 
FM widespread index 0.50 0.0001 
FM symptom severity scale 0.41 0.002 
Disease duration 0.03 0.83 
RA Disease activitya 0.41 0.002 
Swollen joint count 0.25 0.07 
Tender joint count 0.32 0.02 
CRP 0.18 0.19 
Current overall painb 0.09 0.52 
Current Fatiguec 0.26 0.06 
Chronic fatigued 0.40 0.002 
Depressione 0.10 0.46 
Sleep disturbancef 0.31 0.02 
aDisease activity score 28; b Current pain NRS; cCurrent fatigue 0-10 numerical rating scale (NRS); 
dChalder Fatigue Scale; eHospital anxiety & depression scale; fJenkin’s sleep scale; gpearson 
correlation r all except CRP which is spearman correlation rho due to distribution   
 
